Safety, pharmacokinetic, pharmacodynamic and efficacy of subcutaneous single dose of AMG 181 in patients with mild to moderate ulcerative colitis

Trial Profile

Safety, pharmacokinetic, pharmacodynamic and efficacy of subcutaneous single dose of AMG 181 in patients with mild to moderate ulcerative colitis

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Abrilumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top